Paclitaxel News and Research

RSS

Paclitaxel is a drug used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used together with another drug to treat non-small cell lung cancer. Paclitaxel is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent. Also called Taxol.

The Paclitaxel compound is extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). Check for active clinical trials or closed clinical trials using this agent.

Pfizer to present study findings from its expanded breast cancer portfolio

Pfizer Oncology announced today that it will be presenting study findings evaluating several compounds including those from its newly expanded breast cancer portfolio following the recent acquisition of Wyeth, focusing on the needs of multiple breast cancer patient populations at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) being held December 9 – 13.

4 Dec 2009

Genta to supply Ganite for new CF clinical trial

Genta Incorporated announced that the Company will supply Ganite® (gallium nitrate injection) for a new clinical trial that will be initiated in patients with cystic fibrosis (CF) who may develop serious infections.

2 Dec 2009

'Suicide gene E' reduces potent drug dosage in cancer patients

Researchers at the University of Granada have found a suicide gene, called 'gene E', which leads to the death of tumour cells derived from breast, lung and colon cancer, and prevents their growth. The importance of this new gene is that its use to fight cancer can reduce the potent drugs that are currently used, so that could mean more effective treatment for cancer.

25 Nov 2009

Breast cancer patients treated with chemotherapy drug Taxol more likely to develop chronic neuropathic pain

Breast cancer patients treated with the chemotherapy drug Taxol (paclitaxel) are more likely to develop chronic neuropathic pain, according to research published in The Journal of Pain, the peer review publication of the American Pain Society.

24 Nov 2009

Genta announces preliminary results from study of Genasense Injection for advanced melanoma

Genta Incorporated announced preliminary results that show a high objective response rate in a pilot study of patients with advanced melanoma that incorporates the Company’s lead oncology product, Genasense® (oblimersen sodium) Injection, administered for the first time as a 1-hour high-dose intravenous (IV) infusion.

20 Nov 2009

New data on Synta Pharmaceuticals' elesclomol presented at the AACR-NCI-EORTC Conference

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today presented new data on the mechanism of action of elesclomol, a first-in-class oxidative stress inducer, at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics in Boston, Mass.

18 Nov 2009

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical data presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics shows that STA-9090, a novel, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated strong activity in multiple tumor models.

18 Nov 2009

Press conference highlights emerging treatments in pancreatic cancer

As part of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Thompson will moderate a press conference on emerging treatments in pancreatic cancer on Tuesday, Nov. 17, 2009, in Room 202 of the Hynes Convention Center in Boston, Mass., from 1:00 p.m. to 2:00 p.m. ET.

18 Nov 2009

Study to test anti-tumor effects of AEOL 10150 initiated

Aeolus Pharmaceuticals, Inc. announced today the initiation of a study to test the anti-tumor effects of AEOL 10150 when combined with radiation and chemotherapy in nude mice bearing human non-small cell lung cancer (NSCLC) xenografts.

18 Nov 2009

Oncolytics Biotech's REOLYSIN combined with paclitaxel and carboplatin well tolerated for advanced cancers

Oncolytics Biotech Inc. today announced updated results from a Phase I/II U.K. trial (REO 011) of REOLYSIN(R) combined with paclitaxel/carboplatin for patients with advanced cancers in a poster presentation at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference being held in Boston, Massachusetts.

17 Nov 2009

Genentech submits sBLAs to the FDA for Avastin

Genentech, Inc., a wholly-owned member of the Roche Group, today announced that the company submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer (first-line treatment). One sBLA is based on the Phase III study AVADO that investigated Avastin in combination with docetaxel chemotherapy.

17 Nov 2009

Genta announces financial results for the third quarter of 2009, reduces workforce to cut payroll costs

Genta Incorporated today announced financial results for the quarter and nine months ended September 30, 2009. The Company also announced a restructuring, reduction in workforce, and re-ordering of clinical development priorities.

16 Nov 2009

Genta announces Phase 3 trial results of Genasense

Genta Incorporated today announced preliminary results from AGENDA, the Company’s Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. AGENDA is a randomized, double-blind, placebo-controlled trial of dacarbazine (DTIC) administered with or without Genasense® in patients who have not previously received chemotherapy.

16 Nov 2009

Angiotech Pharmaceuticals reports financial results for the third quarter ended September 30, 2009

Angiotech Pharmaceuticals, Inc. today announced its financial results for the third quarter ended September 30, 2009.

9 Nov 2009

Abraxis BioScience reports $96.6 million net revenues for third quarter of 2009

Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the third quarter ending September 30, 2009.

5 Nov 2009

FDA grants Abraxis BioScience orphan drug designation for ABRAXANE

Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced that the Office of Orphan Products Development of the Food and Drug Administration (FDA) has granted orphan drug designation to the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the treatment of pancreatic cancer as well as stage IIB-IV melanoma.

5 Nov 2009

Oncolytics Biotech reports financial results for the third quarter of 2009

Oncolytics Biotech Inc. today announced its financial results for the three and nine-month periods ended September 30, 2009.

5 Nov 2009

Exelixis to present 13 abstracts of its development candidates at the 2009 AACR-NCI-EORTC Conference

Exelixis, Inc. announced today that thirteen abstracts related to the company’s development candidates have been accepted for presentation at the 2009 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is being held November 15-19 in Boston. Interim data from ongoing phase 1 clinical trials of XL147 and XL765 will be reported in four poster presentations.

4 Nov 2009

Positive results from Genta's Phase 3 trial of Genasense

Genta Incorporated today announced top-line results from AGENDA, the Company’s Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. AGENDA is a randomized, double-blind, placebo-controlled trial of dacarbazine administered with or without Genasense® in patients who have not previously received chemotherapy.

29 Oct 2009

NCCN Guidelines for breast cancer does not recommend prophylactic mastectomy in women

Despite a recent study finding that an increasing number of women who had cancer in one breast are opting to have the other breast removed, the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology(TM) for Breast Cancer discourages prophylactic mastectomy in women except for those considered high risk.

29 Oct 2009

Paclitaxel News and Research

Further Reading

Pfizer to present study findings from its expanded breast cancer portfolio

Genta to supply Ganite for new CF clinical trial

'Suicide gene E' reduces potent drug dosage in cancer patients

Breast cancer patients treated with chemotherapy drug Taxol more likely to develop chronic neuropathic pain

Genta announces preliminary results from study of Genasense Injection for advanced melanoma

New data on Synta Pharmaceuticals' elesclomol presented at the AACR-NCI-EORTC Conference

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

Press conference highlights emerging treatments in pancreatic cancer

Study to test anti-tumor effects of AEOL 10150 initiated

Oncolytics Biotech's REOLYSIN combined with paclitaxel and carboplatin well tolerated for advanced cancers

Genentech submits sBLAs to the FDA for Avastin

Genta announces financial results for the third quarter of 2009, reduces workforce to cut payroll costs

Genta announces Phase 3 trial results of Genasense

Angiotech Pharmaceuticals reports financial results for the third quarter ended September 30, 2009

Abraxis BioScience reports $96.6 million net revenues for third quarter of 2009

FDA grants Abraxis BioScience orphan drug designation for ABRAXANE

Oncolytics Biotech reports financial results for the third quarter of 2009

Exelixis to present 13 abstracts of its development candidates at the 2009 AACR-NCI-EORTC Conference

Positive results from Genta's Phase 3 trial of Genasense

NCCN Guidelines for breast cancer does not recommend prophylactic mastectomy in women

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News